Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2022; 10(19): 6417-6427
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6417
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6417
Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
Ying Chen, Mei Sun, Department of Pediatric Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Chen Y and Sun M were gastroenterologists, conceptualized the study, reviewed the literature of eosinophilic gastroenteritis, and drafted the manuscript; Chen Y searched the computerized database of our hospital, collected the patients’ data, and analyzed the data; and all authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Institutional Review Board of ShengJing Hospital of China Medical University (No. 2020PS806K).
Informed consent statement: The requirement for written informed consent was waived by the Institutional Review Board due to the respective nature of this study. All procedures performed in the present study were in accordance with Declaration of Helsinki.
Conflict-of-interest statement: The authors declare that there is no conflict of interest to disclose.
Data sharing statement: The data used and analyzed in this study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mei Sun, MD, Chief Doctor, Department of Pediatric Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sunmei_shenyang@163.com
Received: August 13, 2021
Peer-review started: August 13, 2021
First decision: November 11, 2021
Revised: November 23, 2021
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: July 6, 2022
Peer-review started: August 13, 2021
First decision: November 11, 2021
Revised: November 23, 2021
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: July 6, 2022
Core Tip
Core Tip: Pediatric eosinophilic gastroenteritis is a rare inflammatory disorder, and there is still no standard treatment guideline. Based on our treatment experience and analysis, the level of eosinophil infiltration may be an important factor affecting the treatment outcome. Methylprednisolone/montelukast is still the best treatment for children with lower eosinophil percentage (< 14%). Budesonide can be considered as the initial or relapse treatment for children with high eosinophil infiltration (> 14%).